Table 3:

List of clinical trials and their current status during the years 2015–2020 using TREM-1 and TREM-2 as pathological biomarkers in biological samples of patients with various diseases.

TREM-1
Condition	Sample type	Sponsors	Starting date	Status	Number of enrolled subjects	Outcome measures	ClinicalTrials.gov Identifier
COVID-19	Blood	Central Hospital, Nancy, France	Sept-10–2020	Not yet recruiting	1000	Prognostic value of TREM-1 pathway activation on clinical worsening	NCT04544891
Periodontitis	Crevicular fluid	Central Hospital, Nancy, France	April-2016	Completed	60	Average concentration of sTREM-1 in crevicular fluid	NCT02873949
Fever of unknown origin	Blood	Beijing Friendship Hospital,China	Mar-01–2016	Unknown	80	Inflammatory markers TREM-1, IL-1 and IL-6 in patients with fever of unknown origin	NCT02695914
Neonatal Sepsis	Blood	Assiut University, Egypt	Jan-07–2019	Not yet recruiting	50	Mean difference of neutrophil CD64 expression and sTREM-1 before and after treatment	NCT03795285
Prosthetic infections	Blood	Instituto Ortopedico Galeazzi, Italy	Sept-01–2018	Recruiting	130	Differences in serum concentration of IL-6 and TREM-1 before and after treatment	NCT03769337
Acute kidney injury	Urine	Chinese People’s Liberation Army General Hospital	Jan-2016	Unknown	500	Urine sTREM-1	NCT02920736
TREM-2
Periodontitis	Crevicular fluid	Central Hospital, Nancy, France	April-2016	Completed	60	Average concentration of TREM-2 in crevicular fluid	NCT02873949